secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2022-06-28T23:59:59+00:00
Accession:  0001437749-22-016082
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharma reports positive Altitude Trial results for TSC; appoints Raven Jaeger as CRO
--------------------------------------------------------------------------------

- TSC 2.5 mg/kg dose showed positive effects on pH (p<0.1 vs placebo) and lactate at end of exercise under simulated 15,000 ft hypoxia.
- Post-exercise recovery improved for pH, lactate, and oxygen saturation (SpO2) at 10 minutes with 2.5 mg/kg dose.
- TSC was safe and well tolerated with no serious adverse events across all doses.
- Results support planned Phase 2 Hypoxic Tumor Trial initiation in H2 2022; discussions with FDA ongoing.
- Employment agreement for CRO Raven Jaeger effective May 18, 2022 includes severance of 1.5x base salary + bonus upon change of control and 12-month non-compete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/0001437749-22-016082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774922016082/dffn20220627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-016082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer